User menu

Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.

Bibliographic reference de la Brassinne, Michel ; Ghislain pierre, Pierre-Dominique ; Lambert, Jo L W ; Lambert, Julien ; Segaert, Siegfried ; et. al. Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.. In: Journal of Dermatological Treatment, Vol. 27, no.2, p. 128-133 (2016)
Permanent URL http://hdl.handle.net/2078.1/184805
  1. Christophers Enno, Segaert Siegfried, Milligan Gary, Molta Charles T., Boggs Robert, Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study, 10.3109/09546634.2012.697112
  2. Smolen Josef S, Landewé Robert, Breedveld Ferdinand C, Buch Maya, Burmester Gerd, Dougados Maxime, Emery Paul, Gaujoux-Viala Cécile, Gossec Laure, Nam Jackie, Ramiro Sofia, Winthrop Kevin, de Wit Maarten, Aletaha Daniel, Betteridge Neil, Bijlsma Johannes W J, Boers Maarten, Buttgereit Frank, Combe Bernard, Cutolo Maurizio, Damjanov Nemanja, Hazes Johanna M W, Kouloumas Marios, Kvien Tore K, Mariette Xavier, Pavelka Karel, van Riel Piet L C M, Rubbert-Roth Andrea, Scholte-Voshaar Marieke, Scott David L, Sokka-Isler Tuulikki, Wong John B, van der Heijde Désirée, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, 10.1136/annrheumdis-2013-204573
  3. Yanai Henit, Hanauer Stephen B, Assessing Response and Loss of Response to Biological Therapies in IBD, 10.1038/ajg.2011.103
  4. Brezinski Elizabeth A., Armstrong April W., Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy, 10.1371/journal.pone.0033486
  5. Ramirez-Fort MK, Clin Exp Rheumatol, 31, S63 (2013)
  6. Gordon Kenneth B., Gottlieb Alice B., Leonardi Craig L., Elewski Boni E., Wang Andrea, Jahreis Angelika, Zitnik Ralph, Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy, 10.1080/09546630500472838
  7. Abuchar A, J Drugs Dermatol, 11, 950 (2012)
  8. Ortonne J.-P., Taïeb A., Ormerod A.D., Robertson D., Foehl J., Pedersen R., Molta C., Freundlich B., Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept, 10.1111/j.1365-2133.2009.09238.x
  9. Papp K., Crowley J., Ortonne J.-P., Leu J., Okun M., Gupta S.R., Gu Y., Langley R.G., Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy : Retreatment with adalimumab for psoriasis, 10.1111/j.1365-2133.2010.10139.x
  10. Vender R, J Drugs Dermatol, 10, 396 (2011)
  11. Gottlieb Alice B., Kalb Robert E., Blauvelt Andrew, Heffernan Michael P., Sofen Howard L., Ferris Laura Korb, Kerdel Francisco A., Calabro Stephen, Wang Jim, Kerkmann Urs, Chevrier Marc, The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study, 10.1016/j.jaad.2011.10.020
  12. Strober Bruce E., Poulin Yves, Kerdel Francisco A., Langley Richard G., Gu Yihua, Gupta Shiraz R., Okun Martin M., Papp Kim A., Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study, 10.1016/j.jaad.2010.03.009
  13. Clemmensen A., Spon M., Skov L., Zachariae C., Gniadecki R., Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris : Efficacy of ustekinumab in a clinical practice, 10.1111/j.1468-3083.2010.03914.x
  14. Pivarcsi A., Meisgen F., Xu N., Ståhle M., Sonkoly E., Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy, 10.1111/bjd.12381
  15. Gedebjerg A, Johansen C, Kragballe K, Iversen L, IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab, 10.2340/00015555-1440
  16. Quaglino P., Ortoncelli M., Comessatti A., Ponti R., Novelli M., Bergallo M., Costa C., Cicchelli S., Savoia P., Bernengo M.G., Circulating CD4+CD25brightFOXP3+ T Cells Are Up-Regulated by Biological Therapies and Correlate with the Clinical Response in Psoriasis Patients, 10.1159/000238305
  17. Jókai Hajnalka, Szakonyi József, Kontár Orsolya, Barna Gábor, Inotai Dóra, Kárpáti Sarolta, Holló Péter, Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis, 10.1111/exd.12093
  18. Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F, Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases, 10.1038/tpj.2012.53
  19. Kanelleas A., Liapi C., Katoulis A., Stavropoulos P., Avgerinou G., Georgala S., Economopoulos T., Stavrianeas N. G., Katsambas A., The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept : Inflammatory markers in patients with psoriasis treated with etanercept, 10.1111/j.1365-2230.2011.04131.x
  20. Chiu H.-Y., Wang T.-S., Chan C.-C., Cheng Y.-P., Lin S.-J., Tsai T.-F., Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis, 10.1111/bjd.13056
  21. Talamonti M., Botti E., Galluzzo M., Teoli M., Spallone G., Bavetta M., Chimenti S., Costanzo A., Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab, 10.1111/bjd.12331
  22. Nast Alexander, Boehncke Wolf-Henning, Mrowietz Ulrich, Ockenfels Hans-Michael, Philipp Sandra, Reich Kristian, Rosenbach Thomas, Sammain Adel, Schlaeger Martin, Sebastian Michael, Sterry Wolfram, Streit Volker, Augustin Matthias, Erdmann Ricardo, Klaus Joachim, Koza Joachim, Muller Siegrid, Orzechowski Hans-Dieter, Rosumeck Stefanie, Schmid-Ott Gerhard, Weberschock Tobias, Rzany Berthold, S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update : Preface, 10.1111/j.1610-0387.2012.07919.x
  23. Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C. E. M., Nast A., Franke J., Antoniou C., Arenberger P., Balieva F., Bylaite M., Correia O., Daudén E., Gisondi P., Iversen L., Kemény L., Lahfa M., Nijsten T., Rantanen T., Reich A., Rosenbach T., Segaert S., Smith C., Talme T., Volc-Platzer B., Yawalkar N., Definition of treatment goals for moderate to severe psoriasis: a European consensus, 10.1007/s00403-010-1080-1
  24. Puig L., Obesity and psoriasis: body weight and body mass index influence the response to biological treatment : Psoriasis and biologicals in heavy patients, 10.1111/j.1468-3083.2011.04065.x
  25. Esposito Maria, Giunta Alessandro, Mazzotta Annamaria, Zangrilli Arianna, Babino Graziella, Bavetta Mauro, Perricone Roberto, Chimenti Sergio, Chimenti Maria Sole, Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study, 10.1159/000345623
  26. Reich K., Puig L., Paul C., Kragballe K., Luger T., Lambert J., Chimenti S., Girolomoni G., Nicolas J.-F., Rizova E., Brunori M., Mistry S., Bergmans P., Barker J., , One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis, 10.1111/bjd.12643
  27. Richards Helen L, Fortune Dónal G, Griffiths Christopher E.M, Main Chris J, The contribution of perceptions of stigmatisation to disability in patients with psoriasis, 10.1016/s0022-3999(00)00210-5
  28. Warren R.B., Kleyn C.E., Gulliver W.P., Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course : Cumulative life course impairment in psoriasis: patient perspectives, 10.1111/j.1365-2133.2011.10280.x
  29. Vender Ron, Lynde Charles, Gilbert Martin, Ho Vincent, Sapra Sheetal, Poulin-Costello Melanie, Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice, 10.1177/120347541201600609
  30. Wakkee M, Br J Dermatol, 159, 426 (2008)
  31. Abuabara Katrina, Wan Joy, Troxel Andrea B., Shin Daniel B., Van Voorhees Abby S., Bebo Bruce F., Krueger Gerald G., Callis Duffin Kristina, Gelfand Joel M., Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis, 10.1016/j.jaad.2012.07.007
  32. Schäfer I, Eur J Dermatol, 20, 62 (2010)
  33. Ribera M., Daudén E., Puig L., Briones V. García-Patos, Herranz J.M., Bordas X., Vanaclocha F., Diseño y validación de un cuestionario para medir la satisfacción con el tratamiento del paciente con psoriasis moderada y grave: estudio NEODERMA, 10.1016/j.ad.2010.03.028
  34. Ragnarson Tennvall G, Hjortsberg C, Bergman A, Bjarnason A, Heikkilä H, Hjelmgren J, Svensson Åke, Are Treatment Satisfaction, Quality of Life, and Self-assessed Disease Severity Relevant Parameters for Patient Registries? Experiences from Finnish and Swedish Patients with Psoriasis, 10.2340/00015555-1094
  35. Schaarschmidt Marthe-Lisa, Patient Preferences for Psoriasis Treatments : Process Characteristics Can Outweigh Outcome Attributes, 10.1001/archdermatol.2011.309
  36. Schaarschmidt M.-L., Umar N., Schmieder A., Terris D.D., Goebeler M., Goerdt S., Peitsch W.K., Patient preferences for psoriasis treatments: impact of treatment experience : Treatment experience impacts patient preferences, 10.1111/j.1468-3083.2011.04440.x
  37. Umar Nasir, Litaker David, Schaarschmidt Marthe-Lisa, Peitsch Wiebke K, Schmieder Astrid, Terris Darcey D, Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology, 10.1186/1472-6963-12-1
  38. Menting Stef P., van Lümig Paula P. M., de Vries Anna-Christa Q., van den Reek Juul M. P. A., van der Kleij Desiree, de Jong Elke M. G. J., Spuls Phyllis I., Lecluse Lidian L. A., Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis : One-Year Follow-up, 10.1001/jamadermatol.2013.8347
  39. ADIŞEN Esra, ARAL Arzu, AYBAY Cemalettin, GÜRER Mehmet Ali, Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study : Anti-infliximab antibodies in psoriasis patients, 10.1111/j.1346-8138.2010.00882.x
  40. Cozzani E, G Ital Dermatol Venereol, 148, 171 (2013)
  41. Bito T., Nishikawa R., Hatakeyama M., Kikusawa A., Kanki H., Nagai H., Sarayama Y., Ikeda T., Yoshizaki H., Seto H., Adachi A., Horikawa T., Oka M., Nishigori C., Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis, 10.1111/bjd.12791
  42. Mahil S.K., Arkir Z., Richards G., Lewis C.M., Barker J.N., Smith C.H., Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study, 10.1111/bjd.12341
  43. Lecluse Lidian L. A., Driessen Rieke J. B., Spuls Phyllis I., de Jong Elke M. G. J., Stapel Steven O., van Doorn Martijn B. A., Bos Jan D., Wolbink Gert-Jan, Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis, 10.1001/archdermatol.2009.347
  44. Takahashi Hidetoshi, Tsuji Hitomi, Ishida-Yamamoto Akemi, Iizuka Hajime, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, 10.1111/j.1346-8138.2012.01679.x
  45. Tyring Stephen, Gordon Kenneth B., Poulin Yves, Langley Richard G., Gottlieb Alice B., Dunn Meleana, Jahreis Angelika, Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis, 10.1001/archderm.143.6.719
  46. Hsu L., Snodgrass B.T., Armstrong A.W., Antidrug antibodies in psoriasis: a systematic review, 10.1111/bjd.12654
  47. Hsu Leeyen, Armstrong April W, Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response, 10.1586/1744666x.2013.836060
  48. Levin Ethan C., Gupta Rishu, Brown Gabrielle, Malakouti Mona, Koo John, Biologic fatigue in psoriasis, 10.3109/09546634.2013.826341
  49. Meyer M, Zachariae C, Bendtzen K, Skov L, Lack of Anti-drug Antibodies in Patients with Psoriasis Well-controlled on Long-term Treatment with Tumour Necrosis Factor Inhibitors, 10.2340/00015555-1376
  50. Pink A.E., Fonia A., Allen M.H., Smith C.H., Barker J.N.W.N., Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study : ANAs and anti-TNF-α treatment failure in psoriasis, 10.1111/j.1365-2133.2009.09563.x
  51. Hoffmann J.H.O., Hartmann M., Enk A.H., Hadaschik E.N., Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction : Autoantibodies as predictors for loss of response and anti-infliximab status, 10.1111/j.1365-2133.2011.10555.x
  52. Lora Viviana, Bonaguri Chiara, Gisondi Paolo, Sandei Franca, Battistelli Luisita, Russo Annalisa, Melegari Alessandra, Trenti Tommaso, Lippi Giuseppe, Girolomoni Giampiero, Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab, 10.1007/s12026-013-8410-2
  53. Chan Sue Ann, Hussain Fawad, Lawson Linda G., Ormerod Anthony D., Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities, 10.3109/09546634.2011.607425
  54. Bhosle Monali J., Feldman Steven R., Camacho Fablan T., Timothy Whitmire J., Nahata Milap C., Balkrishnan Rajesh, Medication adherence and health care costs associated with biologics in Medicaid‐enrolled patients with psoriasis, 10.1080/09546630600954594
  55. West C, Dermatol Online J, 19, 18182 (2013)
  56. Sandoval LF, J Drugs Dermatol, 12, 1090 (2013)
  57. Noiles K, J Drugs Dermatol, 8, 329 (2009)
  58. van den Reek J.M.P.A., Zweegers J., Kievit W., Otero M.E., van Lümig P.P.M., Driessen R.J.B., Ossenkoppele P.M., Njoo M.D., Mommers J.M., Koetsier M.I.A., Arnold W.P., Sybrandy-Fleuren B.A.M., Kuijpers A.L.A., Andriessen M.P.M., van de Kerkhof P.C.M., Seyger M.M.B., de Jong E.M.G.J., ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network, 10.1111/bjd.13087
  59. Gniadecki R., Kragballe K., Dam T.N., Skov L., Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris : Adherence to treatment with biologics in patients with psoriasis, 10.1111/j.1365-2133.2011.10213.x
  60. Esposito M., Gisondi P., Cassano N., Ferrucci G., Del Giglio M., Loconsole F., Giunta A., Vena G.A., Chimenti S., Girolomoni G., Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study, 10.1111/bjd.12422
  61. Menting S.P., Sitaram A.S., Bonnerjee-van der Stok H.M., de Rie M.A., Hooft L., Spuls Ph.I., Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis, 10.1111/bjd.13001
  62. Gniadecki R., Bang B., Bryld L.E., Iversen L., Lasthein S., Skov L., Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris, 10.1111/bjd.13343
  63. Altobelli E., Marziliano C., Fargnoli M.C., Petrocelli R., Maccarone M., Chimenti S., Peris K., Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features : Current frequency of treatments in Italian psoriatic patients, 10.1111/j.1468-3083.2011.04196.x
  64. Schmieder Astrid, Schaarschmidt Marthe-Lisa, Umar Nasir, Terris Darcy D., Goebeler Matthias, Goerdt Sergij, Peitsch Wiebke K., Comorbidities significantly impact patients’ preferences for psoriasis treatments, 10.1016/j.jaad.2011.08.023
  65. Laws P.M., Downs A.M., Parslew R., Dever B., Smith C.H., Barker J.N., Moriarty B., Murphy R., Kirby B., Burden A.D., McBride S., Anstey A.V., O’Shea S., Ralph N., Buckley C., Griffiths C.E.M., Warren R.B., Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland : Practical experience of ustekinumab in the treatment of psoriasis, 10.1111/j.1365-2133.2011.10638.x
  66. Puig L., Tratamiento de la psoriasis en placas moderada a grave con fármacos biológicos: análisis del sobrecoste de la intensificación temporal frente a cambio a otro biológico en caso de fracaso secundario, 10.1016/j.ad.2013.10.014